Classes
DEA Class; Rx
Common Brand Names; Zarontin
- Anticonvulsants, Succinimide
Description
Oral succinimide anticonvulsant
Used for the treatment of absence seizures
May increase the frequency of grand mal seizures when used alone in mixed types of epilepsy
Indications
Indicated for the treatment of absence seizures.
Contraindications
Hypersensitivity
Adverse Effects
Common
Dizziness
Headache
Somnolence
Anorexia
Diarrhea
GI upset
Nausea
Vomiting
Less Common
Ataxia, confusion, drowsiness, sleep disturbance
Gum hypertrophy, hiccoughs, swelling of tongue
Blood dyscrasias including aplastic anemia
Allergic reaction
Urticaria
Pruritic erythematous rashes
Blurred vision, myopia
Rare
Psychosis
Seizure
Suicidal thoughts and behavior
Stevens-Johnson syndrome
Systemic lupus erythematosus
Hirsutism
Warnings
Do not discontinue rapidly; proceed slowly when increasing or decreasing dosage, as well as when adding or eliminating other medications; abrupt withdrawal of anticonvulsant medication may precipitate absence (petit mal) status
When used alone in mixed types of epilepsy, therapy may increase frequency of grand mal seizures in some patients
Blood dyscrasias may occur; perform periodic blood counts; should signs and/or symptoms of infection (e.g., sore throat, fever) develop, consider blood counts
Cases of systemic lupus erythematosus reported with use of drug; the physician should be alert to this possibility
Serious dermatologic reactions reported including Stevens-Johnson syndrome (SJS); onset usually within 28 days, but can occur later; discontinue therapy at first sign of rash, unless rash is clearly not drug-related; if signs or symptoms suggest SJS, use of this drug should not be resumed; consider alternative therapy
Drug reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi organ hypersensitivity, reported; some fatal or life-threatening; early manifestations of hypersensitivity (e.g. fever, lymphadenopathy) may be present even though rash is not evident; if such signs or symptoms appear, the patient should be evaluated immediately and therapy discontinued if an alternative etiology for the signs or symptoms cannot be established
Pregnancy and Lactation
Drug crosses placenta; reports suggest an association between use of anticonvulsant drugs by women with epilepsy and elevated incidence of birth defects in children born to these women
The drug is excreted in human breast milk; because effects of ethosuximide on nursing infant are unknown, use caution when administering to a nursing mother; the drug should be used in nursing mothers only if the benefits clearly outweigh the risks
Maximum Dosage
1.5 g/day PO.
1.5 g/day PO.
1.5 g/day PO.
3 to 11 years: 1.5 g/day PO.
1 to 2 years: Safety and efficacy have not been established.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Ethosuximide
capsule
- 250mg
syrup
- 250mg/5mL